CSCatarina Santos

Catarina Santos

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Catarina Santos has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Diagnóstico tardio de síndrome de Gitelman em paciente idoso: identificação de uma nova variante patogênica no SLC12A3

    by Lígia Ribeiro, Micael Pompermayer, Catarina Santos, Joana Coutinho

    RESUMO A síndrome de Gitelman (SG) é uma tubulopatia hereditária, perdedora de sal e hipocalêmica, causada sobretudo por variantes bialélicas com perda de função no gene SLC12A3. Apesar de ser classicamente diagnosticada na adolescência, seu reconhecimento pode ser tardio. Apresentamos o caso de um homem de 74 anos com antecedentes de hipocalemia, cuja avaliação diagnóstica revelou hipocalemia, hipomagnesemia, alcalose metabólica, hipocalciúria e hiperaldosteronismo hiperreninêmico secundário, compatíveis com perda renal de potássio. Dada a apresentação tardia, o principal desafio foi a necessidade de distinguir uma tubulopatia hereditária das causas adquiridas comuns de hipocalemia. Foi realizado teste genético, que identificou uma deleção homozigótica com desvio do quadro de leitura (out-of-frame), até então não descrita, no éxon 25 do gene SLC12A3, prevendo-se que resulte em perda de função da proteína e, portanto, seja patogênica. O tratamento com suplementação associada à espironolactona permitiu melhoria bioquímica sustentada e estabilidade clínica durante o seguimento a longo prazo. Este caso realça que a SG deve ser considerada em pacientes com hipocalemia crônica inexplicada, independentemente da idade, e que o teste genético é essencial para o diagnóstico definitivo.

  • Open Access

    Late diagnosis of Gitelman syndrome in an elderly patient: identification of a novel SLC12A3 pathogenic variant

    by Lígia Ribeiro, Micael Pompermayer, Catarina Santos, Joana Coutinho

    Gitelman syndrome (GS) is an inherited salt-wasting, hypokalemic tubulopathy caused mainly by biallelic loss-of-function variants in the SLC12A3 gene. Despite being classically diagnosed in adolescence, delayed recognition may occur. We present the case of a 74-year-old man with a history of hypokalemia, in whom the diagnostic evaluation revealed hypokalemia, hypomagnesemia, metabolic alkalosis, hypocalciuria, and secondary hyperreninemic hyperaldosteronism, consistent with renal potassium wasting. Given the late presentation, the main challenge was the need to distinguish an inherited tubulopathy from common acquired causes of hypokalemia. Genetic testing was performed, identifying a previously unreported homozygous out-of-frame deletion in exon 25 of the SLC12A3 gene, predicted to result in loss of protein function and therefore to be pathogenic. Treatment with supplementation plus spironolactone achieved sustained biochemical improvement and clinical stability during long-term follow-up. This case highlights that GS should be considered in patients with chronic unexplained hypokalemia regardless of age, and that genetic testing is essential for definitive diagnosis.

  • Open Access

    TH1 Cell Frequency and Neutrophil-to-Lymphocyte Ratio in Hemodialysis: Potential Contributions to Patient Monitoring

    by Inês Rodrigues Barreto, Andreia Monteiro, Ernesto Fernandes Rocha, Catarina Reis Santos, Ana Mafalda Fonseca

    Introduction: Patients undergoing hemodialysis (HD) often exhibit an impaired cellular immune response, which may contribute to an increased susceptibility to infections and other complications. Th1 cells, a subset of T-helper cells, play a crucial role in cellular immunity. However, the modulation of Th1 cells by HD treatment remains unclear. Objective: This study aims to investigate the levels of circulating T cells, especially Th1 cells, and the neutrophil-to-lymphocyte ratio (NLR) in HD patients. Methods: We recruited 26 HD patients and 10 healthy volunteers. Demographical data were collected, and peripheral blood samples were analyzed. Absolute blood cell counts were determined, and T-cell populations were identified using flow cytometry. Th1 cells were defined as IFN-γ-producing CD4+ T cells after in vitro activation, and NLR was calculated through the ratio between the neutrophil and lymphocyte counts measured in peripheral blood. Results: We have observed a significant decrease in Th1 subpopulation frequency in HD patients, as well as significant correlations between immunological and demographic parameters, among which are the NLR values and the absolute values of T-cell subsets. Conclusions: These results seem to clarify the role of Th1 cells in modulating the immune responses of hemodialysis-treated patients, potentially considering its frequency as an indicator for CKD development.


  • Open Access

    Standard Doses of Cholecalciferol Reduce Glucose and Increase Glutamine in Obesity-Related Hypertension: Results of a Randomized Trial

    by Catarina Santos, Rui Carvalho, Ana Mafalda Fonseca, Miguel Castelo Branco, Marco Alves, Ivana Jarak

    In arterial hypertension, the dysregulation of several metabolic pathways is closely associated with chronic immune imbalance and inflammation progression. With time, these disturbances lead to the development of progressive disease and end-organ involvement. However, the influence of cholecalciferol on metabolic pathways as a possible mechanism of its immunomodulatory activity in obesity-related hypertension is not known. In a phase 2, randomized, single-center, 24-week trial, we evaluated, as a secondary outcome, the serum metabolome of 36 age- and gender-matched adults with obesity-related hypertension and vitamin D deficiency, before and after supplementation with cholecalciferol therapy along with routine medication. The defined endpoint was the assessment of circulating metabolites using a nuclear magnetic resonance-based metabolomics approach. Univariate and multivariate analyses were used to evaluate the systemic metabolic alterations caused by cholecalciferol. In comparison with normotensive controls, hypertensive patients presented overall decreased expression of several amino acids (p < 0.05), including amino acids with ketogenic and glucogenic properties as well as aromatic amino acids. Following cholecalciferol supplementation, increases were observed in glutamine (p < 0.001) and histidine levels (p < 0.05), with several other amino acids remaining unaffected. Glucose (p < 0.05) and acetate (p < 0.05) decreased after 24 weeks in the group taking the supplement, and changes in the saturation of fatty acids (p < 0.05) were also observed, suggesting a role of liposoluble vitamin D in lipid metabolism. Long-term cholecalciferol supplementation in chronically obese and overweight hypertensives induced changes in the blood serum metabolome, which reflected systemic metabolism and may have fostered a new microenvironment for cell proliferation and biology. Of note, the increased availability of glutamine may be relevant for the proliferation of different T-cell subsets.


  • Tough Decision Making in Pembrolizumab-Associated Acute Interstitial Nephritis: A Case Report

    by João Grilo, Joana Coutinho, Mário Góis, Catarina Santos, Rui Filipe, Ernesto Rocha

    Pembrolizumab is an immune checkpoint inhibitor used as a cancer therapy. The incidence of immune related adverse events in patients receiving immune checkpoint inhibitors can be as high as 59%–85%. Renal adverse effects are uncommon, but the incidence of kidney toxicity related to pembrolizumab is rising as the use of this agent becomes more frequent. We present an uncommon case of biopsy-proven acute interstitial nephritis secondary to pembrolizumab in a patient with metastatic squamous cell carcinoma at the time of his fourth scheduled cycle. Despite the good initial tumor response, pembrolizumab had to be suspended and the patient started on corticosteroids with an initial good response. On his own initiative, the patient stopped prednisolone early, leading to a rebound acute kidney injury. Pembrolizumab was not reintroduced for the risk of further renal function worsening. His clinical status declined due to the progression of the neoplastic disease, and he was referred for palliative care. This case illustrates the importance of systematizing some key points in the approach to acute interstitial nephritis secondary to pembrolizumab: the role of the differential diagnosis of acute kidney injury in a patient under an immune checkpoint inhibitor, the role of glucocorticoids and the controversy about rechallenging this drug after a related acute interstitial nephritis.

  • Open Access

    In obese hypertensives cholecalciferol inhibits circulating TH17 cells but not macrophage infiltration on adipose tissue

    by Catarina Santos, Andreia Monteiro, Ricardo Rodrigues, Catarina Ferreira, Joana Coutinho, Rui Filipe, Sância Ramos, Miguel Castelo Branco, Mafalda Fonseca


  • Open Access

    Hemodynamic patterns in obesity associated hypertension

    by Catarina Santos, Pedro Marques da Silva